Israel’s SciSparc to commence a Phase 2a clinical trial of its SCI-110 (formerly THX-110) treatment for patients with Alzheimer’s disease (AD) and agitation. The study will be conducted at the Israeli Medical Center for Alzheimer’s.

https://www.prnewswire.com/il/news-releases/scisparc-to-commence-phase-iia-clinical-trial-of-sci-110-for-the-treatment-of-alzheimers-disease-and-agitation-301326828.html